Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Effects of Miricell Supplementation on Biomarkers of Healthy Aging and Autophagy

23 czerwca 2026 zaktualizowane przez: Nutraland USA, Inc.

The goal of this clinical trial is to learn if a dietary supplement called Miricell works to improve cellular health and signs of healthy aging in adults. It will also learn about the safety of Miricell.

The main questions it aims to answer are:

  • Does Miricell improve markers of autophagy, which is the body's natural process for recycling damaged cells?
  • Does Miricell support brain health, metabolic health, and visible signs of aging?
  • What medical problems, if any, do participants experience while taking Miricell?

Researchers will compare Miricell to a placebo (a look-alike capsule that contains no active ingredients) to see if Miricell works better to support healthy aging.

Participants will:

  • Take either one Miricell capsule or a placebo every day for 12 weeks with a morning meal.
  • Visit the research clinic four times over the course of the study for checkups and tests.
  • Complete memory and thinking tests, track their daily physical activity, and give blood samples to measure health changes.

Przegląd badań

Szczegółowy opis

This randomized, double-blind, placebo-controlled, parallel-group clinical trial evaluates the physiological impacts of a standardized spermidine ingredient (Miricell®) over a 12-week intervention period.

Participants are randomized in a 1:1 ratio into one of two parallel groups. To ensure rigorous double-blind conditions, investigators, research site staff, and participants remain masked to group allocations throughout the duration of the trial. Investigational products are supplied in identical-looking, opaque capsules packaged in coded bottles to prevent accidental unblinding. The randomization schedule is maintained securely and will only be broken in the event of a medical emergency requiring immediate knowledge of the treatment assignment.

To minimize confounding variables related to endogenous autophagy activation and variable background polyamine intake, strict lifestyle compliance measures are enforced across both groups:

  • Participants receive detailed instructions to avoid altering their baseline intake of polyamine-rich foods (such as aged cheeses, fermented soy, and specific grains/mushrooms) to ensure nutritional stability.
  • Dietary tracking is deployed at multiple intervals to longitudinally verify caloric and macronutrient consistency throughout the study period.
  • Prior to scheduled laboratory evaluations, participants must replicate their individual 24-hour baseline diet, abstain from alcohol and heavy physical exertion for 24 hours, avoid caffeine for 12 hours, and maintain a strict 10-hour overnight fast.

Participant safety is continuously monitored by the investigative medical staff. All local or systemic adverse events are systematically evaluated and categorized by clinical severity. Internal data monitoring and quality assurance reviews are performed regularly by designated site staff to guarantee protocol adherence and regulatory compliance. Backup blood samples are kept from each visit to protect against any laboratory or processing errors.

Typ studiów

Interwencyjne

Zapisy (Szacowany)

70

Faza

  • Nie dotyczy

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

Lokalizacje studiów

    • Ohio
      • Canfield, Ohio, Stany Zjednoczone, 44406
        • Rekrutacyjny
        • The Center for Applied Health Sciences
        • Kontakt:

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

  • Dorosły
  • Starszy dorosły

Akceptuje zdrowych ochotników

Tak

Opis

INCLUSION CRITERIA:

  • Provide voluntary signed and dated informed consent.
  • Be in fair health as determined by medical history and routine blood chemistries.
  • Age between the ages of 40 and 70 (inclusive).
  • Body weight of at least 110 pounds.
  • Normotensive (seated, resting systolic blood pressure <140 mm Hg and diastolic blood pressure < 90 mm Hg. If the first measurement is slightly elevated above these limits, the subject will be given a brief (5-minute) rest period, and two more measurements will be taken. The average of all three measurements will be used to determine eligibility.
  • Normal seated, resting heart rate (<90 per minute).
  • Willing to duplicate their previous 24-hour diet, refrain from alcohol for 24 hours, exercise for 24 hours prior to each trial, caffeine for 12 hours prior to each trial, and fast for 10 hours prior to each of the treatments.
  • Participant agrees to maintain existing dietary and physical activity patterns throughout the study period.
  • Participant is willing and able to comply with the study protocol.
  • If a dietary supplement was initiated within the past month, the participant is willing to discontinue supplement use followed by a 2-week washout prior to participation in the study.
  • Able to provide an adequate blood draw.

EXCLUSION CRITERIA:

  • Use of probiotics, postbiotics or antibiotics within the past month.
  • A history of unstable or new-onset cardiovascular/cardiorespiratory, liver, or renal disease.
  • The participant's alcohol consumption is more than two standard alcoholic drinks per day or more than 10 drinks per week or has a history of drug/alcohol abuse or dependence.
  • History of diabetes (any form) or any endocrine disorder.
  • Fasting blood sugar of > 125 mg/dL.
  • Current smokers who smoke 11 or more cigarettes per day (i.e. light smokers will be enrolled if they meet all other criteria).
  • History of hyperparathyroidism or an untreated thyroid disease.
  • History of malignancy in the previous five years except for non-melanoma skin cancer (basal cell cancer or squamous cell cancer of the skin).
  • Chronic inflammatory condition or disease (e.g., rheumatoid arthritis, Crohn's Disease, ulcerative colitis, lupus, HIV/AIDS, etc.).
  • Previous medical diagnosis of gout or fibromyalgia.
  • Any female who is pregnant, trying to become pregnant, is less than/or equal to 120 days postpartum, or any current women who are nursing.
  • Women who participate in this study must agree to the use of contraception for the duration of the study, and any sexually active woman will have to take a negative pregnancy test prior to enrolling. Women of childbearing age (any woman prior to menopause), regardless of their use of contraception, will be provided a urine pregnancy test kit at their screening visit and take the test in private using the female lavatory after signing an informed consent.
  • Known allergy or sensitivity to any ingredient in the test formulations as listed on the product label.
  • Any other diseases or conditions that, in the opinion of the medical staff, could confound the primary endpoints or place the subject at increased risk of harm if they were to participate.

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Podstawowa nauka
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Potroić

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Aktywny komparator: Miricell™
Participants assigned to this arm will receive one capsule of the active branded spermidine supplement (Miricell) daily for a total duration of 12 weeks.
Branded spermidine ingredient (Miricell® Rice Germ Extract) administered orally at a dose of 3.3 mg/day. Provided as a single opaque capsule to be ingested daily with water in the morning with a meal.
Komparator placebo: Placebo
Participants assigned to this arm will receive one look-alike placebo capsule daily for a total duration of 12 weeks.
Placebo capsule (microcrystalline cellulose) packaged in an identical-looking, opaque capsule to be ingested daily with water in the morning with a meal.

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Serum Beclin-1 Concentration
Ramy czasowe: Baseline (Week 0), Week 6, and Week 12
Measures the change from baseline in serum Beclin-1 levels to assess autophagy activation.
Baseline (Week 0), Week 6, and Week 12
Serum ULK1 Concentration
Ramy czasowe: Baseline (Week 0), Week 6, and Week 12
Measures the change from baseline in serum ULK-1 levels to assess autophagy activation.
Baseline (Week 0), Week 6, and Week 12

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Brain-Derived Neurotrophic Factor (BDNF) Concentration
Ramy czasowe: Baseline (Week 0), Week 6, and Week 12
Measures the change from baseline in serum BDNF levels to evaluate indices of neuroprotection.
Baseline (Week 0), Week 6, and Week 12
High-Sensitivity C-Reactive Protein (hs-CRP) Concentration
Ramy czasowe: Baseline (Week 0), Week 6, and Week 12
Measures the change from baseline in hs-CRP levels to evaluate systemic inflammatory status and cardio-metabolic health.
Baseline (Week 0), Week 6, and Week 12
Fasting Insulin Concentration
Ramy czasowe: Baseline (Week 0), Week 6, and Week 12
Measures the change from baseline in fasting insulin levels to calculate changes in Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)
Baseline (Week 0), Week 6, and Week 12
Cognitive Function Score via CNS Vital Signs
Ramy czasowe: Baseline (Week 0), Week 6, and Week 12
Evaluation of neurocognitive performance domains using the computerized CNS Vital Signs testing platform.
Baseline (Week 0), Week 6, and Week 12
Patient-Reported Outcomes Measurement Information System - Cognitive Function (PROMIS-CF) Score
Ramy czasowe: Baseline (Week 0), Week 6, and Week 12
Participant-reported evaluation of cognitive capabilities utilizing the standardized PROMIS-CF Short Form 8a questionnaire
Baseline (Week 0), Week 6, and Week 12
Patient-Reported Outcomes Measurement Information System - Cognitive Function - Abilities (PROMIS-CF-A) Score
Ramy czasowe: Baseline (Week 0), Week 6, and Week 12
Participant-reported evaluation of cognitive abilities utilizing the standardized PROMIS-CF-A Short Form 8a questionnaire.
Baseline (Week 0), Week 6, and Week 12
Lipid Panel Metrics
Ramy czasowe: Baseline (Week 0), Week 6, and Week 12
Standard clinical panel measuring fasting serum cholesterol fractions (Total, LDL, HDL) and triglycerides to evaluate lipid homeostasis.
Baseline (Week 0), Week 6, and Week 12

Inne miary wyników

Miara wyniku
Opis środka
Ramy czasowe
Phenotypic Age (PhenoAge)
Ramy czasowe: Baseline (Week 0), Week 6, and Week 12
An assessment of biological age calculated using a validated multi-variable algorithm incorporating chronological age alongside specific clinical biomarkers from the complete blood count (CBC), comprehensive metabolic panel (CMP), and hs-CRP.
Baseline (Week 0), Week 6, and Week 12
Subjective Hair and Nail Health Likert Scores
Ramy czasowe: Baseline (Week 0), Week 6, and Week 12
Evaluation of subjective visible signs of aging assessed via custom Likert-style questionnaires rating hair and nail appearance/quality.
Baseline (Week 0), Week 6, and Week 12
Quality of Life Score (SF-36)
Ramy czasowe: Baseline (Week 0), Week 6, and Week 12
Evaluation of general health-related quality of life metrics using the standardized 36-Item Short Form Survey (SF-36).
Baseline (Week 0), Week 6, and Week 12
Body Composition via Bioelectrical Impedance Analysis (BIA)
Ramy czasowe: Baseline (Week 0), Week 6, and Week 12
Assessment of shifts in fat mass and fat-free mass using an InBody 570 analyzer to track physiological changes over time.
Baseline (Week 0), Week 6, and Week 12

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

9 stycznia 2026

Zakończenie podstawowe (Szacowany)

1 września 2026

Ukończenie studiów (Szacowany)

1 września 2026

Daty rejestracji na studia

Pierwszy przesłany

23 czerwca 2026

Pierwszy przesłany, który spełnia kryteria kontroli jakości

23 czerwca 2026

Pierwszy wysłany (Rzeczywisty)

30 czerwca 2026

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

30 czerwca 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

23 czerwca 2026

Ostatnia weryfikacja

1 czerwca 2026

Więcej informacji

Terminy związane z tym badaniem

Inne numery identyfikacyjne badania

  • NLMIRI-01-2025

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

NIE

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj